Trial | NCT00630643  Report issue

Title

NI-0401 in Active Crohn's Disease
A Phase I/IIa, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NI-0401 in Patients With Moderate to Severe Active Crohn´s Disease

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    ni-0401 ...

  • Study Participants

    40
The purpose of the study is to assess the safety and tolerability of daily intravenous NI-0401 treatment, compared to matching placebo. And to assess the ability of NI-0401 to modulate the CD3 complex on T-cells.
Study Started
Jan 31
2006
Primary Completion
Dec 31
2007
Study Completion
Dec 31
2007
Last Update
Mar 07
2008
Estimate

Biological NI-0401 (anti-CD3 mAB)

0.05 mg up to 10 mg

Drug Placebo

Placebo

1 Placebo Comparator

2 Experimental

Criteria 

Main Inclusion Criteria:

Men and women between 18 and 70 years of age.
Crohn's Disease Activity Index (CDAI) between 220 and 450.
Raised plasma CRP level.
Endoscopic inflammation.
Crohn's disease of at least 6 months duration, with colitis, ileitis, or ileocolitis, confirmed by endoscopy and histology within 28 days of study day 1.

Main Exclusion criteria

Have received or are planned to receive immunization with a live vaccine within 6 weeks prior to receiving study drug and 12 weeks after treatment cessation.

Concomitant disease:

Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurological or cerebral disease (including a history of seizure disorders or ongoing chronic active conditions such as chronic active hepatitis)
Previous diagnosis of, or known, malignancies
Severe infections, such as hepatitis, pneumonia or pyelonephritis, in the past three months. Less serious infections in the past 3 months, such as acute upper respiratory tract infection (colds) or uncompliant urinary tract infection are permitted at the discretion of the investigator
Active infection requiring antibiotic therapy
Serum anti HCV positive, serum HBsAg positive, serum anti-HIV positive
History of opportunistic infections such as herpes zoster within 2 months prior to screening, evidence of acute CMV or EBV, active Pneumocystic Carinii
History of active tuberculosis (TB) or currently undergoing treatment for TB. Patients with a positive TB skin test or chest x-ray are ineligible. Patients with a history of bacille Calmette Guerin (BCG) vaccination and a newly positive TB skin test or a chest X-ray showing fibrotic lesions consistent with previous TB are ineligible. The PPD skin test must be read between 48 and 72 hours
Stool examination positive for enteric pathogens, pathogenic ova or parasites, or Clostridium Difficile toxin within 4 weeks prior to Study Day 1
No Results Posted